SlideShare uma empresa Scribd logo
1 de 7
Find Industry reports, Company profiles
ReportLinker                                                                          and Market Statistics
                                               >> Get this Report Now by email!



IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012
Published on August 2012

                                                                                                              Report Summary

IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012


Summary


Global Markets Direct's pharmaceuticals report, 'IMPAX Laboratories, Inc. - Product Pipeline Review - 2012' provides data on the
IMPAX Laboratories, Inc.'s research and development focus. The report includes information on current developmental pipeline,
complete with latest updates, and features on discontinued and dormant projects.


This report is built using data and information sourced from Global Markets Direct's proprietary databases, IMPAX Laboratories, Inc.'s
corporate website, SEC filings, investor presentations and featured press releases, both from IMPAX Laboratories, Inc. and
industry-specific third party sources, put together by Global Markets Direct's team.


Scope


- IMPAX Laboratories, Inc. - Brief IMPAX Laboratories, Inc. overview including business description, key information and facts, and its
locations and subsidiaries.
- Review of current pipeline of IMPAX Laboratories, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities,
across the globe.
- Product profiles for late stage and clinical stage products of IMPAX Laboratories, Inc. with complete description of the product's
developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the IMPAX Laboratories, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate IMPAX Laboratories, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of IMPAX Laboratories, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the IMPAX Laboratories, Inc.'s R&D portfolio and develop key strategic
initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with IMPAX Laboratories, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of IMPAX Laboratories, Inc. and identify potential opportunities in those areas.




IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012 (From Slideshare)                                                     Page 1/7
Find Industry reports, Company profiles
ReportLinker                                                                         and Market Statistics
                                               >> Get this Report Now by email!



                                                                                                     Table of Content

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
IMPAX Laboratories, Inc. Snapshot 6
IMPAX Laboratories, Inc. Overview 6
Key Information 6
Key Facts 6
IMPAX Laboratories, Inc. ' Research and Development Overview 7
Key Therapeutic Areas 7
IMPAX Laboratories, Inc. ' Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products ' Monotherapy 10
IMPAX Laboratories, Inc. ' Pipeline Products Glance 11
IMPAX Laboratories, Inc. ' Late Stage Pipeline 11
Registration Filed Products/Combination Treatment Modalities 11
IMPAX Laboratories, Inc. Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
IMPAX Laboratories, Inc. ' Drug Profiles 13
IPX056 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
IPX066 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
IPX159 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
IMPAX Laboratories, Inc. ' Pipeline Products by Route of Administration 18
IMPAX Laboratories, Inc. ' Pipeline Products By Mechanism of Action 19
IMPAX Laboratories, Inc. ' Recent Pipeline Updates 20
IMPAX Laboratories, Inc. - Dormant Projects 23
IMPAX Laboratories, Inc. ' Company Statement 24
IMPAX Laboratories, Inc. ' Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
IMPAX Laboratories, Inc., Recent Developments 27
IMPAX Laboratories, Inc.- Press Release 27
Apr 18, 2012: Impax To Presents Data From ASCEND-PD Phase III Study Of IPX066 At American Academy Of Neurology
Conference 27
Feb 23, 2012: FDA Accepts NDA Filing For IPX066 For Treatment Of Idiopathic Parkinson's Disease 27



IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012 (From Slideshare)                                      Page 2/7
Find Industry reports, Company profiles
ReportLinker                                                                         and Market Statistics
                                               >> Get this Report Now by email!

Dec 02, 2009: Impax Laboratories Acquires Rights to Abbreviated New Drug Applications 28
Oct 27, 2009: Impax Pharmaceuticals Commences Phase III trial Of IPX066 Drug In PD patients 28
Oct 07, 2009: Impax Laboratories Settles Pending Litigation for FLOMAX 29
Oct 05, 2009: Impax Laboratories Receives Tentative FDA Approval for Generic FLOMAX 0.4mg Capsules 29
Oct 01, 2009: Impax Starts Shipment Of Generic Adderall XR Capsules 29
Sep 23, 2009: Impax Pharmaceuticals Presents Positive Results Of Phase II Trial Of IPX066 30
Sep 21, 2009: Impax Pharmaceuticals Reports Positive Results of Phase II Trial of IPX066, a Novel Formulation of
Carbidopa-Levodopa for Parkinson's Disease 30
Aug 05, 2009: Impax Laboratories Receives Final FDA Approval for Generic Depakote Extended-Release 500mg Tablets 31
Jun 08, 2009: Impax Pharmaceuticals Presents Phase II Data at 13th International Congress Of Parkinson's Disease And Movement
Disorders 31
May 19, 2009: Impax Receives FDA Approval for Generic Precose Tablets, 25 mg, 50 mg and 100 mg 32
May 06, 2009: Impax Receives Final FDA Approval for Generic Depakote Extended-Release 250mg Tablets 32
Apr 22, 2009: Impax Pharmaceuticals Presents Positive Achievements On Its Two Leading Brand Product Candidates Including
IPX066 33
Apr 20, 2009: Impax Pharmaceuticals Commences A Phase III Trial Of IPX066 33
Apr 20, 2009: Impax Pharmaceuticals Reports Positive Achievements On Its Leading Brand Product Candidate IPX056 33
Mar 20, 2009: Impax Confirms Patent Lawsuit Relating to Doryx Tablets 150 mg 34
Mar 17, 2009: Impax Confirms ANDA Filing For Doryx Tablets 150mg 34
Jan 26, 2009: IMPAX Receives Final FDA Approval For Omeprazole 40 Mg Capsules 34
Financial Deals Landscape 35
IMPAX Laboratories, Inc., Deals Summary 35
IMPAX Laboratories, Inc., Pharmaceuticals & Healthcare, Deal Details 37
Asset Transactions 37
Impax Labs Acquires Abbreviated New Drug Applications Rights From Watson Pharma 37
Impax Labs Acquires ANDA Rights Of Dronabinol From Cobalt Labs 39
Partnerships 40
Impax Labs Enters Into Development And Distribution Agreement With Tolmar 40
IMPAX Lab Enters Into Co-Development Agreement With TOLMAR 42
IMPAX Labs Enters Into Co-Marketing Agreement With Banner Pharmacaps 43
Impax Labs Enters Into Co-Development Agreement With Perrigo 44
IGI Labs Enters Into Co-Development Agreement With IMPAX Labs 45
IMPAX Labs Amends Co-Promotion Agreement With Wyeth 46
IMPAX Labs Enters Into Co-Promotion Agreement With Wyeth 47
Medicis Pharma Enters Into An Agreement With IMPAX Labs 48
Intec Pharma Enters Into Co-Development Agreement With IMPAX Labs 49
Impax Labs Enters Into Co-Promotion Agreement With Shire For Carbatrol 50
IMPAX Labs Enters Into Co-Marketing Agreement With Shire For Adderall XR 51
Licensing Agreements 52
Impax Pharma Enters Into Licensing Agreement With AstraZeneca For Zomig 52
GlaxoSmithKline Enters Into Licensing Agreement With Impax Pharma For IPX066 53
IMPAX Labs Enters Into Licensing Agreement With Endo Pharma 55
Endo Pharma And Penwest Pharma Enter Into Licensing Agreement With Impax Labs 56
Medicis Pharma Enters Into Licensing Agreement With IMPAX Labs 57
Wyeth Enters Into Agreement With IMPAX 58
Impax Labs Enters Into Licensing Agreement With Wyeth 59
Impax Labs Enters Into Licensing Agreement With Purdue Pharma 60
Impax Labs Enters Into Licensing Agreement With DAVA Pharma 61



IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012 (From Slideshare)                                           Page 3/7
Find Industry reports, Company profiles
ReportLinker                                                                         and Market Statistics
                                               >> Get this Report Now by email!

Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 63
Disclaimer 6


List of Tables


IMPAX Laboratories, Inc., Key Information 6
IMPAX Laboratories, Inc., Key Facts 6
IMPAX Laboratories, Inc. ' Pipeline by Indication, 2012 8
IMPAX Laboratories, Inc. ' Pipeline by Stage of Development, 2012 9
IMPAX Laboratories, Inc. ' Monotherapy Products in Pipeline, 2012 10
IMPAX Laboratories, Inc. ' Filed, 2012 11
IMPAX Laboratories, Inc. ' Phase II, 2012 12
IMPAX Laboratories, Inc. ' Pipeline By Route of Administration, 2012 18
IMPAX Laboratories, Inc. ' Pipeline Products By Mechanism of Action, 2012 19
IMPAX Laboratories, Inc. ' Recent Pipeline Updates, 2012 20
IMPAX Laboratories, Inc. - Dormant Developmental Projects,2012 23
IMPAX Laboratories, Inc., Other Locations 26
IMPAX Laboratories, Inc., Subsidiaries 26
IMPAX Laboratories, Inc., Deals Summary 35
Impax Labs Acquires Abbreviated New Drug Applications Rights From Watson Pharma 37
Impax Labs Acquires ANDA Rights Of Dronabinol From Cobalt Labs 39
Impax Labs Enters Into Development And Distribution Agreement With Tolmar 40
IMPAX Lab Enters Into Co-Development Agreement With TOLMAR 42
IMPAX Labs Enters Into Co-Marketing Agreement With Banner Pharmacaps 43
Impax Labs Enters Into Co-Development Agreement With Perrigo 44
IGI Labs Enters Into Co-Development Agreement With IMPAX Labs 45
IMPAX Labs Amends Co-Promotion Agreement With Wyeth 46
IMPAX Labs Enters Into Co-Promotion Agreement With Wyeth 47
Medicis Pharma Enters Into An Agreement With IMPAX Labs 48
Intec Pharma Enters Into Co-Development Agreement With IMPAX Labs 49
Impax Labs Enters Into Co-Promotion Agreement With Shire For Carbatrol 50
IMPAX Labs Enters Into Co-Marketing Agreement With Shire For Adderall XR 51
Impax Pharma Enters Into Licensing Agreement With AstraZeneca For Zomig 52
GlaxoSmithKline Enters Into Licensing Agreement With Impax Pharma For IPX066 53
IMPAX Labs Enters Into Licensing Agreement With Endo Pharma 55
Endo Pharma And Penwest Pharma Enter Into Licensing Agreement With Impax Labs 56
Medicis Pharma Enters Into Licensing Agreement With IMPAX Labs 57
Wyeth Enters Into Agreement With IMPAX 58
Impax Labs Enters Into Licensing Agreement With Wyeth 59
Impax Labs Enters Into Licensing Agreement With Purdue Pharma 60
Impax Labs Enters Into Licensing Agreement With DAVA Pharma 61




IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012 (From Slideshare)                                     Page 4/7
Find Industry reports, Company profiles
ReportLinker                                                                         and Market Statistics
                                               >> Get this Report Now by email!

List of Figures


IMPAX Laboratories, Inc. ' Pipeline by Indication, 2012 8
IMPAX Laboratories, Inc. ' Pipeline by Stage of Development, 2012 9
IMPAX Laboratories, Inc. ' Monotherapy Products in Pipeline, 2012 10
IMPAX Laboratories, Inc. - Pipeline Products By Mechanism of Action, 2012 19




IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012 (From Slideshare)                                     Page 5/7
Find Industry reports, Company profiles
ReportLinker                                                                                and Market Statistics
                                               >> Get this Report Now by email!
              Fax Order Form
              To place an order via fax simply print this form, fill in the information below and fax the completed form to:
                           Europe, Middle East and Africa : + 33 4 37 37 15 56
                           Asia, Oceania and America : + 1 (805) 617 17 93
              If you have any questions please visit http://www.reportlinker.com/notify/contact


              Order Information
              Please verify that the product information is correct and select the format(s) you require.

                    IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012




              Product Formats
              Please select the product formats and the quantity you require.

                                      1 User License--USD 1 500.00                 Quantity: _____



                                      Site License--USD 3 000.00                   Quantity: _____



                                      Corporate License--USD 4 500.00              Quantity: _____




              Contact Information
              Please enter all the information below in BLOCK CAPITALS


              Title:                    Mr                        Mrs         Dr             Miss           Ms                 Prof

              First Name:                    _____________________________ Last Name: __________________________________

              Email Address:                __________________________________________________________________________

              Job Title:                    __________________________________________________________________________

              Organization:                 __________________________________________________________________________

              Address:                      __________________________________________________________________________

              City:                         __________________________________________________________________________

              Postal / Zip Code:             __________________________________________________________________________

              Country:                      __________________________________________________________________________

              Phone Number:                 __________________________________________________________________________

              Fax Number:                  __________________________________________________________________________




IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012 (From Slideshare)                                                           Page 6/7
Find Industry reports, Company profiles
ReportLinker                                                                                         and Market Statistics
                                               >> Get this Report Now by email!
              Payment Information
              Please indicate the payment method, you would like to use by selecting the appropriate box.




                     Payment by credit card                         Card Number: ______________________________________________


                                                                    Expiry Date     __________ / _________


                                                                    CVV Number _____________________


                                                                    Card Type (ex: Visa, Amex…) _________________________________




                     Payment by wire transfer                       Crédit Mutuel
                                                                    RIB : 10278 07314 00020257701 89
                                                                    BIC : CMCIFR2A
                                                                    IBAN : FR76 1027 8073 1400 0202 5770 189




                      Payment by check                              UBIQUICK SAS
                                                                    16 rue Grenette – 69002 LYON, FRANCE




                                   Customer signature:

                                    




              Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
              http://www.reportlinker.com/index/terms




                                                                       Please fax this form to:

                                                        Europe, Middle East and Africa : + 33 4 37 37 15 56

                                                           Asia, Oceania and America : + 1 (805) 617 17 93




IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012 (From Slideshare)                                                         Page 7/7

Mais conteúdo relacionado

Mais de ReportLinker.com

Wireless Infrastructure: Market Shares, Strategies, and Forecasts, Worldwide,...
Wireless Infrastructure: Market Shares, Strategies, and Forecasts, Worldwide,...Wireless Infrastructure: Market Shares, Strategies, and Forecasts, Worldwide,...
Wireless Infrastructure: Market Shares, Strategies, and Forecasts, Worldwide,...ReportLinker.com
 
Global Electric Resistance Welded Pipes Industry
Global Electric Resistance Welded Pipes IndustryGlobal Electric Resistance Welded Pipes Industry
Global Electric Resistance Welded Pipes IndustryReportLinker.com
 
Global Wireless Gaming Industry
Global Wireless Gaming IndustryGlobal Wireless Gaming Industry
Global Wireless Gaming IndustryReportLinker.com
 
Hyperalgesia Global Clinical Trials Review, H1, 2013
Hyperalgesia Global Clinical Trials Review, H1, 2013Hyperalgesia Global Clinical Trials Review, H1, 2013
Hyperalgesia Global Clinical Trials Review, H1, 2013ReportLinker.com
 
Genital Herpes Global Clinical Trials Review, H1, 2013
Genital Herpes Global Clinical Trials Review, H1, 2013Genital Herpes Global Clinical Trials Review, H1, 2013
Genital Herpes Global Clinical Trials Review, H1, 2013ReportLinker.com
 
The Future of Direct Communications Technologies and Proximity-based Applicat...
The Future of Direct Communications Technologies and Proximity-based Applicat...The Future of Direct Communications Technologies and Proximity-based Applicat...
The Future of Direct Communications Technologies and Proximity-based Applicat...ReportLinker.com
 
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...Competing in the European Molecular Diagnostics Market: France, Germany, Ital...
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...ReportLinker.com
 
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...ReportLinker.com
 
Bradycardia Global Clinical Trials Review, H1, 2013
Bradycardia Global Clinical Trials Review, H1, 2013Bradycardia Global Clinical Trials Review, H1, 2013
Bradycardia Global Clinical Trials Review, H1, 2013ReportLinker.com
 
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013ReportLinker.com
 
China iron ore mining industry, 2013
China iron ore mining industry, 2013China iron ore mining industry, 2013
China iron ore mining industry, 2013ReportLinker.com
 
Global Renewable Energy Report
Global Renewable Energy ReportGlobal Renewable Energy Report
Global Renewable Energy ReportReportLinker.com
 

Mais de ReportLinker.com (20)

Samsung customer loyalty
Samsung customer loyaltySamsung customer loyalty
Samsung customer loyalty
 
Project Caf
Project CafProject Caf
Project Caf
 
Project Caf
Project CafProject Caf
Project Caf
 
Wireless Infrastructure: Market Shares, Strategies, and Forecasts, Worldwide,...
Wireless Infrastructure: Market Shares, Strategies, and Forecasts, Worldwide,...Wireless Infrastructure: Market Shares, Strategies, and Forecasts, Worldwide,...
Wireless Infrastructure: Market Shares, Strategies, and Forecasts, Worldwide,...
 
 
 
Thisisatest
ThisisatestThisisatest
Thisisatest
 
Global Electric Resistance Welded Pipes Industry
Global Electric Resistance Welded Pipes IndustryGlobal Electric Resistance Welded Pipes Industry
Global Electric Resistance Welded Pipes Industry
 
Global Wireless Gaming Industry
Global Wireless Gaming IndustryGlobal Wireless Gaming Industry
Global Wireless Gaming Industry
 
Hyperalgesia Global Clinical Trials Review, H1, 2013
Hyperalgesia Global Clinical Trials Review, H1, 2013Hyperalgesia Global Clinical Trials Review, H1, 2013
Hyperalgesia Global Clinical Trials Review, H1, 2013
 
Genital Herpes Global Clinical Trials Review, H1, 2013
Genital Herpes Global Clinical Trials Review, H1, 2013Genital Herpes Global Clinical Trials Review, H1, 2013
Genital Herpes Global Clinical Trials Review, H1, 2013
 
The Future of Direct Communications Technologies and Proximity-based Applicat...
The Future of Direct Communications Technologies and Proximity-based Applicat...The Future of Direct Communications Technologies and Proximity-based Applicat...
The Future of Direct Communications Technologies and Proximity-based Applicat...
 
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...Competing in the European Molecular Diagnostics Market: France, Germany, Ital...
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...
 
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...
 
Bradycardia Global Clinical Trials Review, H1, 2013
Bradycardia Global Clinical Trials Review, H1, 2013Bradycardia Global Clinical Trials Review, H1, 2013
Bradycardia Global Clinical Trials Review, H1, 2013
 
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
 
China iron ore mining industry, 2013
China iron ore mining industry, 2013China iron ore mining industry, 2013
China iron ore mining industry, 2013
 
World Biomass Report
World Biomass ReportWorld Biomass Report
World Biomass Report
 
World Biofuels Report
World Biofuels ReportWorld Biofuels Report
World Biofuels Report
 
Global Renewable Energy Report
Global Renewable Energy ReportGlobal Renewable Energy Report
Global Renewable Energy Report
 

IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012

  • 1. Find Industry reports, Company profiles ReportLinker and Market Statistics >> Get this Report Now by email! IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012 Published on August 2012 Report Summary IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012 Summary Global Markets Direct's pharmaceuticals report, 'IMPAX Laboratories, Inc. - Product Pipeline Review - 2012' provides data on the IMPAX Laboratories, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct's proprietary databases, IMPAX Laboratories, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from IMPAX Laboratories, Inc. and industry-specific third party sources, put together by Global Markets Direct's team. Scope - IMPAX Laboratories, Inc. - Brief IMPAX Laboratories, Inc. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of IMPAX Laboratories, Inc. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of IMPAX Laboratories, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the IMPAX Laboratories, Inc.'s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate IMPAX Laboratories, Inc.'s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of IMPAX Laboratories, Inc. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the IMPAX Laboratories, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with IMPAX Laboratories, Inc.. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of IMPAX Laboratories, Inc. and identify potential opportunities in those areas. IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 1/7
  • 2. Find Industry reports, Company profiles ReportLinker and Market Statistics >> Get this Report Now by email! Table of Content Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 IMPAX Laboratories, Inc. Snapshot 6 IMPAX Laboratories, Inc. Overview 6 Key Information 6 Key Facts 6 IMPAX Laboratories, Inc. ' Research and Development Overview 7 Key Therapeutic Areas 7 IMPAX Laboratories, Inc. ' Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products ' Monotherapy 10 IMPAX Laboratories, Inc. ' Pipeline Products Glance 11 IMPAX Laboratories, Inc. ' Late Stage Pipeline 11 Registration Filed Products/Combination Treatment Modalities 11 IMPAX Laboratories, Inc. Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 IMPAX Laboratories, Inc. ' Drug Profiles 13 IPX056 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 IPX066 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 IPX159 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 IMPAX Laboratories, Inc. ' Pipeline Products by Route of Administration 18 IMPAX Laboratories, Inc. ' Pipeline Products By Mechanism of Action 19 IMPAX Laboratories, Inc. ' Recent Pipeline Updates 20 IMPAX Laboratories, Inc. - Dormant Projects 23 IMPAX Laboratories, Inc. ' Company Statement 24 IMPAX Laboratories, Inc. ' Locations And Subsidiaries 26 Head Office 26 Other Locations & Subsidiaries 26 IMPAX Laboratories, Inc., Recent Developments 27 IMPAX Laboratories, Inc.- Press Release 27 Apr 18, 2012: Impax To Presents Data From ASCEND-PD Phase III Study Of IPX066 At American Academy Of Neurology Conference 27 Feb 23, 2012: FDA Accepts NDA Filing For IPX066 For Treatment Of Idiopathic Parkinson's Disease 27 IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 2/7
  • 3. Find Industry reports, Company profiles ReportLinker and Market Statistics >> Get this Report Now by email! Dec 02, 2009: Impax Laboratories Acquires Rights to Abbreviated New Drug Applications 28 Oct 27, 2009: Impax Pharmaceuticals Commences Phase III trial Of IPX066 Drug In PD patients 28 Oct 07, 2009: Impax Laboratories Settles Pending Litigation for FLOMAX 29 Oct 05, 2009: Impax Laboratories Receives Tentative FDA Approval for Generic FLOMAX 0.4mg Capsules 29 Oct 01, 2009: Impax Starts Shipment Of Generic Adderall XR Capsules 29 Sep 23, 2009: Impax Pharmaceuticals Presents Positive Results Of Phase II Trial Of IPX066 30 Sep 21, 2009: Impax Pharmaceuticals Reports Positive Results of Phase II Trial of IPX066, a Novel Formulation of Carbidopa-Levodopa for Parkinson's Disease 30 Aug 05, 2009: Impax Laboratories Receives Final FDA Approval for Generic Depakote Extended-Release 500mg Tablets 31 Jun 08, 2009: Impax Pharmaceuticals Presents Phase II Data at 13th International Congress Of Parkinson's Disease And Movement Disorders 31 May 19, 2009: Impax Receives FDA Approval for Generic Precose Tablets, 25 mg, 50 mg and 100 mg 32 May 06, 2009: Impax Receives Final FDA Approval for Generic Depakote Extended-Release 250mg Tablets 32 Apr 22, 2009: Impax Pharmaceuticals Presents Positive Achievements On Its Two Leading Brand Product Candidates Including IPX066 33 Apr 20, 2009: Impax Pharmaceuticals Commences A Phase III Trial Of IPX066 33 Apr 20, 2009: Impax Pharmaceuticals Reports Positive Achievements On Its Leading Brand Product Candidate IPX056 33 Mar 20, 2009: Impax Confirms Patent Lawsuit Relating to Doryx Tablets 150 mg 34 Mar 17, 2009: Impax Confirms ANDA Filing For Doryx Tablets 150mg 34 Jan 26, 2009: IMPAX Receives Final FDA Approval For Omeprazole 40 Mg Capsules 34 Financial Deals Landscape 35 IMPAX Laboratories, Inc., Deals Summary 35 IMPAX Laboratories, Inc., Pharmaceuticals & Healthcare, Deal Details 37 Asset Transactions 37 Impax Labs Acquires Abbreviated New Drug Applications Rights From Watson Pharma 37 Impax Labs Acquires ANDA Rights Of Dronabinol From Cobalt Labs 39 Partnerships 40 Impax Labs Enters Into Development And Distribution Agreement With Tolmar 40 IMPAX Lab Enters Into Co-Development Agreement With TOLMAR 42 IMPAX Labs Enters Into Co-Marketing Agreement With Banner Pharmacaps 43 Impax Labs Enters Into Co-Development Agreement With Perrigo 44 IGI Labs Enters Into Co-Development Agreement With IMPAX Labs 45 IMPAX Labs Amends Co-Promotion Agreement With Wyeth 46 IMPAX Labs Enters Into Co-Promotion Agreement With Wyeth 47 Medicis Pharma Enters Into An Agreement With IMPAX Labs 48 Intec Pharma Enters Into Co-Development Agreement With IMPAX Labs 49 Impax Labs Enters Into Co-Promotion Agreement With Shire For Carbatrol 50 IMPAX Labs Enters Into Co-Marketing Agreement With Shire For Adderall XR 51 Licensing Agreements 52 Impax Pharma Enters Into Licensing Agreement With AstraZeneca For Zomig 52 GlaxoSmithKline Enters Into Licensing Agreement With Impax Pharma For IPX066 53 IMPAX Labs Enters Into Licensing Agreement With Endo Pharma 55 Endo Pharma And Penwest Pharma Enter Into Licensing Agreement With Impax Labs 56 Medicis Pharma Enters Into Licensing Agreement With IMPAX Labs 57 Wyeth Enters Into Agreement With IMPAX 58 Impax Labs Enters Into Licensing Agreement With Wyeth 59 Impax Labs Enters Into Licensing Agreement With Purdue Pharma 60 Impax Labs Enters Into Licensing Agreement With DAVA Pharma 61 IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 3/7
  • 4. Find Industry reports, Company profiles ReportLinker and Market Statistics >> Get this Report Now by email! Appendix 62 Methodology 62 Coverage 62 Secondary Research 62 Primary Research 62 Expert Panel Validation 62 Contact Us 63 Disclaimer 6 List of Tables IMPAX Laboratories, Inc., Key Information 6 IMPAX Laboratories, Inc., Key Facts 6 IMPAX Laboratories, Inc. ' Pipeline by Indication, 2012 8 IMPAX Laboratories, Inc. ' Pipeline by Stage of Development, 2012 9 IMPAX Laboratories, Inc. ' Monotherapy Products in Pipeline, 2012 10 IMPAX Laboratories, Inc. ' Filed, 2012 11 IMPAX Laboratories, Inc. ' Phase II, 2012 12 IMPAX Laboratories, Inc. ' Pipeline By Route of Administration, 2012 18 IMPAX Laboratories, Inc. ' Pipeline Products By Mechanism of Action, 2012 19 IMPAX Laboratories, Inc. ' Recent Pipeline Updates, 2012 20 IMPAX Laboratories, Inc. - Dormant Developmental Projects,2012 23 IMPAX Laboratories, Inc., Other Locations 26 IMPAX Laboratories, Inc., Subsidiaries 26 IMPAX Laboratories, Inc., Deals Summary 35 Impax Labs Acquires Abbreviated New Drug Applications Rights From Watson Pharma 37 Impax Labs Acquires ANDA Rights Of Dronabinol From Cobalt Labs 39 Impax Labs Enters Into Development And Distribution Agreement With Tolmar 40 IMPAX Lab Enters Into Co-Development Agreement With TOLMAR 42 IMPAX Labs Enters Into Co-Marketing Agreement With Banner Pharmacaps 43 Impax Labs Enters Into Co-Development Agreement With Perrigo 44 IGI Labs Enters Into Co-Development Agreement With IMPAX Labs 45 IMPAX Labs Amends Co-Promotion Agreement With Wyeth 46 IMPAX Labs Enters Into Co-Promotion Agreement With Wyeth 47 Medicis Pharma Enters Into An Agreement With IMPAX Labs 48 Intec Pharma Enters Into Co-Development Agreement With IMPAX Labs 49 Impax Labs Enters Into Co-Promotion Agreement With Shire For Carbatrol 50 IMPAX Labs Enters Into Co-Marketing Agreement With Shire For Adderall XR 51 Impax Pharma Enters Into Licensing Agreement With AstraZeneca For Zomig 52 GlaxoSmithKline Enters Into Licensing Agreement With Impax Pharma For IPX066 53 IMPAX Labs Enters Into Licensing Agreement With Endo Pharma 55 Endo Pharma And Penwest Pharma Enter Into Licensing Agreement With Impax Labs 56 Medicis Pharma Enters Into Licensing Agreement With IMPAX Labs 57 Wyeth Enters Into Agreement With IMPAX 58 Impax Labs Enters Into Licensing Agreement With Wyeth 59 Impax Labs Enters Into Licensing Agreement With Purdue Pharma 60 Impax Labs Enters Into Licensing Agreement With DAVA Pharma 61 IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 4/7
  • 5. Find Industry reports, Company profiles ReportLinker and Market Statistics >> Get this Report Now by email! List of Figures IMPAX Laboratories, Inc. ' Pipeline by Indication, 2012 8 IMPAX Laboratories, Inc. ' Pipeline by Stage of Development, 2012 9 IMPAX Laboratories, Inc. ' Monotherapy Products in Pipeline, 2012 10 IMPAX Laboratories, Inc. - Pipeline Products By Mechanism of Action, 2012 19 IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 5/7
  • 6. Find Industry reports, Company profiles ReportLinker and Market Statistics >> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012 Product Formats Please select the product formats and the quantity you require. 1 User License--USD 1 500.00 Quantity: _____ Site License--USD 3 000.00 Quantity: _____ Corporate License--USD 4 500.00 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________ IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 6/7
  • 7. Find Industry reports, Company profiles ReportLinker and Market Statistics >> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 IMPAX Laboratories, Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 7/7